Inhaled corticosteroids should not be prescribed to all chronic obstructive pulmonary disease patients

Canadian Respiratory Journal

Volumn 10, Issue 3, 2003, Pages 148-149

  Bourbeau, Jean ^a   McIvor, Andrew ^b  

^a MCGILL UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ADRENAL SUPPRESSION; ASTHMA; BONE DENSITY; BONE DISEASE; BONE MINERAL; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL STUDY; CONFERENCE PAPER; DATA ANALYSIS; DISEASE EXACERBATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FRACTURE; GLAUCOMA; HOSPITAL DISCHARGE; HUMAN; INTRAOCULAR HYPERTENSION; LUNG FUNCTION; MEDICAL RESEARCH; MORTALITY; OSTEOPOROSIS; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SKIN BRUISING; SMOKING CESSATION; SYMPTOM; TREATMENT OUTCOME;

EID: 0038515118     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/495751     Document Type: Conference Paper

References (22)

1. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systemic review and meta-analysis. Arch Intern Med 1999;159:941.
2. Hall TG, Kasik JE, Bedell GN, Schaiff RA. The efficacy of inhaled beclomethasone in chronic obstructive airway disease. Pharmacotherapy 1989;9:232-9.
3. Engel T, Heinig JH, Madsen O, Hansen M, Weeke ER. A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis. Eur Respir J 1989;2:935-9.
4. Auffarth B, Postma DS, de Monchy JG, van der Mark TW, Boorsma M, Koeter GH. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax 1991;46:372-7.
5. Wempe JB, Postma DS, Breederveld N, Kort E, van der Mark TW, Koeter GH. Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease. Thorax 1992:616-21.
6. Renkema TEJ, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996;109:1156-62.
7. Llewellyn-Jones CG, Harris TAJ, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996;153:616-21.
8. Boothman-Burrell D, Delany SG, Flannery EM, Hancox RJ, Taylor DR. The efficacy of inhaled corticosteroids in the management of non-asthmatic chronic airflow obstruction. N Z Med J 1997;110:370-3.
9. Weir DC, Gove RI, Robertson AS, Burge PS. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax 1990;45:112-7.
10. Kerstjens HA, Brand PL, Quanjer PH, et al. Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. Thorax 1993;48:722-9.
11. Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest 1995;8:1568-71.
12. Pauwels RA, Lofdahi C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53.
13. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
14. Burge PS, Caverley PM, Jones PW, Spencer S, Andersen JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propitionate in patients with moderate to severe chronic obstructive pulmonary disease. The ISOLDE trial. BMJ 2000;320:1297-303.
15. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
16. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effects of high doses of inhaled steroids on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-9.
17. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
18. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-5.
19. Yildiz F, Kaur AC, Ilgazli A, et al. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 2000;67:71-6.
20. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
21. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-4.
22. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20:819-25.